Kuryk and colleagues recently demonstrated that an Ad5/3 chimeric OAd armed with GMCSF (ONCOS-102) significantly reduced tumor volume when combined with pembrolizumab (anti-PD-L1) in huNOG mice (NOD/Shi-scid/IL-2Rynull) humanized with CD34+ cord blood cells [95]. This evidence concerns the gene CD274 and neoplasm.